Analgesics and Anti-inflammatory Drugs — MCQs

Q: Which of the following is NOT an indication for the use of NSAIDs?

In peptic ulcer disease. **Explanation:** The correct answer is **B. In peptic ulcer disease**. NSAIDs are generally **contraindicated** in patients with peptic ulcers because they inhibit the enzyme Cyclooxygenase-1 (COX-1). COX-1 is responsible for synthesizing cytoprotective prostaglandins ($PGE_2$ and $PGI_2$) in the gastric mucosa. These prostaglandins reduce gastric acid secretion, increase bicarbonate production, and maintain mucosal blood flow. By inhibiting them, NSAIDs compromise the gastric mucosal barrier, leading to erosions, ulceration, and potential perforation or hemorrhage. **Why the other options are incorrect:** * **A. As an analgesic:** NSAIDs are first-line agents for mild-to-moderate pain (e.g., headache, dysmenorrhea, or post-operative pain) by inhibiting $PGE_2$ synthesis, which sensitizes pain receptors. * **C & D. Rheumatoid Arthritis and Osteoarthritis:** NSAIDs are mainstay symptomatic treatments for these conditions. They reduce joint inflammation, swelling, and stiffness by inhibiting COX-2 at the site of inflammation. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Gastric Injury:** NSAIDs cause damage via two pathways: systemic inhibition of protective prostaglandins and direct local irritation (topical effect). * **Prophylaxis:** If an NSAID must be used in a high-risk patient, **Misoprostol** (a $PGE_1$ analog) or a Proton Pump Inhibitor (PPI) is co-administered for mucosal protection. * **Selective COX-2 Inhibitors (e.g., Celecoxib):** These carry a lower risk of GI ulcers but are associated with increased cardiovascular risks. * **Aspirin Sensitivity:** NSAIDs can trigger "Aspirin-Exacerbated Respiratory Disease" (AERD) in asthmatic patients due to a shift in arachidonic acid metabolism toward the leukotriene pathway.

Q: What is the mechanism of action of Aspirin?

Inhibition of TXA2 formation. **Explanation:** **Mechanism of Action:** Aspirin (Acetylsalicylic acid) acts by **irreversibly inhibiting the enzyme Cyclooxygenase (COX-1 and COX-2)** via acetylation of a serine residue. In platelets, this leads to the inhibition of **Thromboxane A2 (TXA2)** synthesis. Since platelets are anucleated and cannot synthesize new enzymes, the inhibition lasts for the entire lifespan of the platelet (approx. 7–10 days). TXA2 is a potent vasoconstrictor and platelet aggregator; thus, its inhibition results in an anti-thrombotic effect. **Analysis of Options:** * **Option B (Correct):** Aspirin reduces TXA2 levels, which is the primary mechanism for its use in secondary prophylaxis of MI and stroke. * **Option A (Incorrect):** While aspirin can inhibit PGI2 (Prostacyclin) in vascular endothelium, PGI2 is a vasodilator and anti-aggregatory agent. At low doses, aspirin selectively inhibits TXA2 more than PGI2 because endothelial cells can regenerate COX enzymes, unlike platelets. * **Option C & D (Incorrect):** Aspirin inhibits, rather than stimulates, TXA2 formation. Consequently, it inhibits (rather than stimulates) platelet aggregation. **High-Yield NEET-PG Pearls:** 1. **Low-dose Aspirin (75–150 mg):** Exhibits anti-platelet effects (selective TXA2 inhibition). 2. **Zero-order Kinetics:** Aspirin follows zero-order elimination at high/toxic doses. 3. **Reye’s Syndrome:** Aspirin is contraindicated in children with viral infections (Varicella/Influenza) due to the risk of hepatic encephalopathy. 4. **Aspirin Triad (Samter’s Triad):** Asthma, Nasal polyposis, and Aspirin hypersensitivity. 5. **Antidote:** There is no specific antidote; treatment for toxicity involves gastric lavage and **urinary alkalinization** (using Sodium Bicarbonate) to enhance excretion.

Q: Which of the following is a new IL-1 antagonist used in rheumatoid arthritis?

Anakinra. **Explanation:** **Anakinra** is the correct answer because it is a recombinant, non-glycosylated form of the human **Interleukin-1 receptor antagonist (IL-1Ra)**. In Rheumatoid Arthritis (RA), IL-1 is a key pro-inflammatory cytokine that mediates cartilage destruction and bone resorption. Anakinra competitively inhibits the binding of IL-1α and IL-1β to the IL-1 type I receptor, thereby reducing the inflammatory response. **Analysis of Incorrect Options:** * **Rituximab (Option B):** This is a chimeric monoclonal antibody against **CD20**, a protein found primarily on the surface of B-cells. It is used in RA cases refractory to TNF inhibitors. * **Teriparatide (Option C):** This is a recombinant form of **Parathyroid Hormone (PTH)**. It is an anabolic agent used for Osteoporosis, not an anti-inflammatory for RA. * **Adalimumab (Option D):** This is a fully human monoclonal antibody directed against **TNF-α** (Tumor Necrosis Factor-alpha), not IL-1 [1]. **High-Yield NEET-PG Pearls:** * **Other IL-1 Inhibitors:** Apart from Anakinra, newer agents include **Canakinumab** (monoclonal antibody against IL-1β) and **Rilonacept** (IL-1 trap). * **Clinical Use:** Anakinra is less commonly used than TNF inhibitors due to its shorter half-life (requires daily subcutaneous injections) and lower efficacy in RA. * **Contraindication:** Never combine IL-1 antagonists with TNF inhibitors (like Adalimumab or Etanercept) due to a significantly increased risk of serious infections [2]. * **Side Effect:** Injection site reactions are the most common adverse effect. DMARDs include a diverse group of small molecule non-biologicals and biological agents used to retard the progression of arthritic tissue destruction [3].

Q: Which of the following NSAIDs is preferred in the treatment of dysmenorrhea?

Mefenamic acid. **Explanation:** **Mefenamic acid** (Option C) is the preferred NSAID for the treatment of primary dysmenorrhea. The underlying pathophysiology of dysmenorrhea involves the overproduction of prostaglandins (specifically $PGF_{2\alpha}$) in the endometrium, leading to uterine hypercontractility and ischemia. Mefenamic acid is uniquely effective because it possesses a **dual mechanism of action**: 1. It inhibits the enzyme **Cyclooxygenase (COX)**, thereby reducing the synthesis of prostaglandins. 2. It acts as an **antagonist at prostaglandin receptors**, directly blocking the action of pre-formed prostaglandins on the myometrium. **Analysis of Incorrect Options:** * **A. Indomethacin:** While a potent COX inhibitor, it is associated with a high incidence of systemic side effects (GI distress, frontal headaches, and dizziness), making it a second-line choice for routine menstrual pain. * **B. Ketorolac:** This is an extremely potent analgesic primarily used for short-term management of severe acute pain (post-operative). It is not the standard of care for dysmenorrhea due to its high risk of nephrotoxicity and GI bleeding. * **D. Naproxen:** Although effective and frequently used for dysmenorrhea due to its long half-life, it lacks the specific receptor-blocking property of Mefenamic acid. **High-Yield Clinical Pearls for NEET-PG:** * **Mefenamic Acid (Fenamate):** Also used in Menorrhagia as it reduces blood loss by 20-30%. * **Side Effect:** A unique side effect of Mefenamic acid is **diarrhea** and occasionally hemolytic anemia. * **DOC for PDA:** Ibuprofen (or Indomethacin) is the drug of choice for the closure of Patent Ductus Arteriosus. * **DOC for Acute Gout:** NSAIDs (like Indomethacin or Naproxen) are first-line, but Mefenamic acid is not typically used.

Q: Which of the following is a spasmolytic analgesic?

Dicyclomine. **Explanation:** **Dicyclomine** is the correct answer because it is a tertiary amine antimuscarinic agent that functions as a **spasmolytic (antispasmodic)**. It works by antagonizing muscarinic (M3) receptors on smooth muscles and exerts a direct relaxant effect on the gastrointestinal tract. In clinical practice, it is frequently used to relieve smooth muscle spasms and associated pain in conditions like irritable bowel syndrome (IBS) and GI colic, earning it the classification of a "spasmolytic analgesic." **Analysis of Incorrect Options:** * **Physostigmine:** This is a reversible anticholinesterase (parasympathomimetic). Instead of relieving spasms, it increases acetylcholine levels, which would actually increase GI motility and potentially worsen cramping. It is primarily used as an antidote for atropine poisoning. * **Tropicamide:** This is a short-acting antimuscarinic used exclusively in ophthalmology as a mydriatic (to dilate the pupil) and cycloplegic. It has no systemic role as a spasmolytic analgesic. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Dicyclomine reduces GI tone and amplitude of contractions without significantly affecting gastric acid secretion. * **Contraindications:** Like all anticholinergics, it should be avoided in patients with **Glaucoma** (can increase intraocular pressure), **Prostatic Hyperplasia** (can cause urinary retention), and **Myasthenia Gravis**. * **Other Spasmolytics:** Other drugs in this category frequently tested include **Hyoscine (Scopolamine)** and **Drotaverine** (a PDE-4 inhibitor).

Q: Gold compounds are used in the management of which condition?

Rheumatoid Arthritis. **Explanation:** **Gold compounds** (Chrysotherapy), such as **Auranofin** (oral) and **Sodium aurothiomalate** (injectable), are classified as older Disease-Modifying Anti-Rheumatic Drugs (DMARDs). **Why Rheumatoid Arthritis (RA) is correct:** Gold compounds work by inhibiting macrophage phagocytosis and lysosomal enzyme release, which slows the progression of bone and cartilage destruction in RA. While they were once a mainstay for inducing remission in active RA, they have largely been replaced by more effective and less toxic agents like Methotrexate. **Analysis of Incorrect Options:** * **Ankylosing Spondylitis:** This is a seronegative spondyloarthropathy. The primary treatments are NSAIDs and TNF-alpha inhibitors (e.g., Etanercept). Gold salts have no proven efficacy in axial skeletal involvement. * **Psoriatic Arthritis:** While some DMARDs are used here, Gold is not a standard or effective treatment for the cutaneous or articular manifestations of psoriasis. * **Rheumatic Arthritis (Rheumatic Fever):** This is an inflammatory response to a Group A Streptococcal infection. The management focuses on antibiotics (Penicillin) and salicylates (Aspirin) for joint pain, not DMARDs. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Gold salts are taken up by macrophages (forming "Aurosomes") and inhibit NF-kB signaling. * **Toxicity (High Yield):** The most common side effects are **dermatitis** (pruritic rash), **nephrotoxicity** (membranous glomerulonephritis leading to proteinuria), and **hematological disorders** (aplastic anemia). * **Current Status:** Gold is now considered a "reserve drug" due to its slow onset of action (3–6 months) and significant side-effect profile.

Q: Which of the following is an analgesic that does not inhibit prostaglandin synthesis?

Nefopam. ### Explanation **1. Why Nefopam is Correct:** Nefopam is a **non-opioid, non-NSAID** centrally acting analgesic. Unlike NSAIDs, its mechanism of action does not involve the inhibition of cyclooxygenase (COX) enzymes or prostaglandin synthesis. Instead, it acts primarily by inhibiting the reuptake of **serotonin, norepinephrine, and dopamine** (triple monoamine reuptake inhibitor). It also modulates NMDA receptors and sodium/calcium channels. This unique profile makes it useful for acute pain management without the gastrointestinal or anti-platelet side effects associated with prostaglandin inhibition. **2. Why the Other Options are Incorrect:** * **Tenoxicam & Piroxicam (Options B & D):** These are long-acting NSAIDs belonging to the **Oxicam** class. They are potent inhibitors of both COX-1 and COX-2 enzymes, thereby reducing prostaglandin synthesis. * **Ketorolac (Option C):** This is a **Pyrrolo-pyrrole** derivative NSAID known for its powerful analgesic efficacy (comparable to low-dose morphine). It is a non-selective COX inhibitor that significantly blocks prostaglandin production. **3. High-Yield Clinical Pearls for NEET-PG:** * **Nefopam & Shivering:** A high-yield clinical use of Nefopam is its effectiveness in treating **post-operative shivering**, as it resets the shivering threshold in the hypothalamus. * **Contraindications:** Due to its sympathomimetic effects (norepinephrine reuptake inhibition), it should be avoided in patients with **convulsions, glaucoma, or those taking MAO inhibitors.** * **Side Effects:** Common side effects include tachycardia, dry mouth, and urinary retention (anticholinergic-like effects). * **Analgesic Ladder:** Nefopam is often used as an "adjunct" in multimodal analgesia to reduce opioid requirements (opioid-sparing effect).

Analgesics and Anti-inflammatory Drugs — MCQs

Analgesics and Anti-inflammatory Drugs Indian Medical PG Practice Questions and MCQs

Question 1: Which of the following is NOT an indication for the use of NSAIDs?

A. As an analgesic
B. In peptic ulcer disease (Correct Answer)
C. Rheumatoid arthritis
D. Osteoarthritis

Explanation: **Explanation:** The correct answer is **B. In peptic ulcer disease**. NSAIDs are generally **contraindicated** in patients with peptic ulcers because they inhibit the enzyme Cyclooxygenase-1 (COX-1). COX-1 is responsible for synthesizing cytoprotective prostaglandins ($PGE_2$ and $PGI_2$) in the gastric mucosa. These prostaglandins reduce gastric acid secretion, increase bicarbonate production, and maintain mucosal blood flow. By inhibiting them, NSAIDs compromise the gastric mucosal barrier, leading to erosions, ulceration, and potential perforation or hemorrhage. **Why the other options are incorrect:** * **A. As an analgesic:** NSAIDs are first-line agents for mild-to-moderate pain (e.g., headache, dysmenorrhea, or post-operative pain) by inhibiting $PGE_2$ synthesis, which sensitizes pain receptors. * **C & D. Rheumatoid Arthritis and Osteoarthritis:** NSAIDs are mainstay symptomatic treatments for these conditions. They reduce joint inflammation, swelling, and stiffness by inhibiting COX-2 at the site of inflammation. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Gastric Injury:** NSAIDs cause damage via two pathways: systemic inhibition of protective prostaglandins and direct local irritation (topical effect). * **Prophylaxis:** If an NSAID must be used in a high-risk patient, **Misoprostol** (a $PGE_1$ analog) or a Proton Pump Inhibitor (PPI) is co-administered for mucosal protection. * **Selective COX-2 Inhibitors (e.g., Celecoxib):** These carry a lower risk of GI ulcers but are associated with increased cardiovascular risks. * **Aspirin Sensitivity:** NSAIDs can trigger "Aspirin-Exacerbated Respiratory Disease" (AERD) in asthmatic patients due to a shift in arachidonic acid metabolism toward the leukotriene pathway.

Question 2: What is the mechanism of action of Aspirin?

A. Inhibition of PGI2 formation
B. Inhibition of TXA2 formation (Correct Answer)
C. Stimulation of TXA2 formation
D. Stimulation of platelet aggregation

Explanation: **Explanation:** **Mechanism of Action:** Aspirin (Acetylsalicylic acid) acts by **irreversibly inhibiting the enzyme Cyclooxygenase (COX-1 and COX-2)** via acetylation of a serine residue. In platelets, this leads to the inhibition of **Thromboxane A2 (TXA2)** synthesis. Since platelets are anucleated and cannot synthesize new enzymes, the inhibition lasts for the entire lifespan of the platelet (approx. 7–10 days). TXA2 is a potent vasoconstrictor and platelet aggregator; thus, its inhibition results in an anti-thrombotic effect. **Analysis of Options:** * **Option B (Correct):** Aspirin reduces TXA2 levels, which is the primary mechanism for its use in secondary prophylaxis of MI and stroke. * **Option A (Incorrect):** While aspirin can inhibit PGI2 (Prostacyclin) in vascular endothelium, PGI2 is a vasodilator and anti-aggregatory agent. At low doses, aspirin selectively inhibits TXA2 more than PGI2 because endothelial cells can regenerate COX enzymes, unlike platelets. * **Option C & D (Incorrect):** Aspirin inhibits, rather than stimulates, TXA2 formation. Consequently, it inhibits (rather than stimulates) platelet aggregation. **High-Yield NEET-PG Pearls:** 1. **Low-dose Aspirin (75–150 mg):** Exhibits anti-platelet effects (selective TXA2 inhibition). 2. **Zero-order Kinetics:** Aspirin follows zero-order elimination at high/toxic doses. 3. **Reye’s Syndrome:** Aspirin is contraindicated in children with viral infections (Varicella/Influenza) due to the risk of hepatic encephalopathy. 4. **Aspirin Triad (Samter’s Triad):** Asthma, Nasal polyposis, and Aspirin hypersensitivity. 5. **Antidote:** There is no specific antidote; treatment for toxicity involves gastric lavage and **urinary alkalinization** (using Sodium Bicarbonate) to enhance excretion.

Question 3: What is the mechanism of analgesia?

A. Nociceptin stimulation (Correct Answer)
B. Nooistatln stimulation
C. Nicotinic & cholinergic receptors
D. Anandamide receptors

Explanation: ### Explanation **Correct Option: A. Nociceptin stimulation** Nociceptin (also known as Orphanin FQ) is an endogenous neuropeptide that acts on the **NOP receptor** (Nociceptin/Orphanin FQ peptide receptor). Although it belongs to the opioid receptor family, it does not bind to classical $\mu$, $\kappa$, or $\delta$ receptors. Nociceptin acts as a potent modulator of pain. While its effects are complex (it can be pro-nociceptive in the spinal cord), its stimulation in specific supraspinal pathways and its role in modern drug development (like **Cevidopline**) are targeted for producing potent analgesia without the typical side effects of classical opioids, such as respiratory depression or physical dependence [3]. **Incorrect Options:** * **B. Nooistatln stimulation:** This is a distractor term with no recognized physiological role in pain modulation or pharmacology. * **C. Nicotinic & cholinergic receptors:** While nicotinic agonists (like Epibatidine) have shown analgesic properties, they are not the primary mechanism for standard analgesia and are limited by high toxicity. Cholinergic stimulation generally relates to the parasympathetic nervous system rather than direct sensory pain inhibition. * **D. Anandamide receptors:** Anandamide is an endogenous cannabinoid that binds to **CB1 and CB2 receptors**. While it plays a role in the "endocannabinoid system" for pain relief, "Anandamide receptors" is a misnomer; the receptors are termed Cannabinoid receptors. **NEET-PG High-Yield Pearls:** * **NOP Receptor:** Formerly known as the "Orphan" receptor (ORL-1). It is G-protein coupled ($G_i/G_o$). * **Triple/Mixed Agonists:** New research focuses on ligands that target $\mu$ and NOP receptors simultaneously to provide "safer" analgesia [3]. * **Endogenous Opioids:** Remember the pairs: **$\mu$** (Endorphins), **$\delta$** (Enkephalins), **$\kappa$** (Dynorphins), and **NOP** (Nociceptin) [1], [2]. Activation of these receptors on nociceptive fibers leads to decreased Ca2+ influx and increased K+ conductance, reducing sensory transmission [2].

Question 4: Which of the following is a new IL-1 antagonist used in rheumatoid arthritis?

A. Anakinra (Correct Answer)
B. Rituximab
C. Teriparatide
D. Adalimumab

Explanation: **Explanation:** **Anakinra** is the correct answer because it is a recombinant, non-glycosylated form of the human **Interleukin-1 receptor antagonist (IL-1Ra)**. In Rheumatoid Arthritis (RA), IL-1 is a key pro-inflammatory cytokine that mediates cartilage destruction and bone resorption. Anakinra competitively inhibits the binding of IL-1α and IL-1β to the IL-1 type I receptor, thereby reducing the inflammatory response. **Analysis of Incorrect Options:** * **Rituximab (Option B):** This is a chimeric monoclonal antibody against **CD20**, a protein found primarily on the surface of B-cells. It is used in RA cases refractory to TNF inhibitors. * **Teriparatide (Option C):** This is a recombinant form of **Parathyroid Hormone (PTH)**. It is an anabolic agent used for Osteoporosis, not an anti-inflammatory for RA. * **Adalimumab (Option D):** This is a fully human monoclonal antibody directed against **TNF-α** (Tumor Necrosis Factor-alpha), not IL-1 [1]. **High-Yield NEET-PG Pearls:** * **Other IL-1 Inhibitors:** Apart from Anakinra, newer agents include **Canakinumab** (monoclonal antibody against IL-1β) and **Rilonacept** (IL-1 trap). * **Clinical Use:** Anakinra is less commonly used than TNF inhibitors due to its shorter half-life (requires daily subcutaneous injections) and lower efficacy in RA. * **Contraindication:** Never combine IL-1 antagonists with TNF inhibitors (like Adalimumab or Etanercept) due to a significantly increased risk of serious infections [2]. * **Side Effect:** Injection site reactions are the most common adverse effect. DMARDs include a diverse group of small molecule non-biologicals and biological agents used to retard the progression of arthritic tissue destruction [3].

Question 5: Which of the following NSAIDs is preferred in the treatment of dysmenorrhea?

A. Indomethacin
B. Ketorolac
C. Mefenamic acid (Correct Answer)
D. Naproxen

Explanation: **Explanation:** **Mefenamic acid** (Option C) is the preferred NSAID for the treatment of primary dysmenorrhea. The underlying pathophysiology of dysmenorrhea involves the overproduction of prostaglandins (specifically $PGF_{2\alpha}$) in the endometrium, leading to uterine hypercontractility and ischemia. Mefenamic acid is uniquely effective because it possesses a **dual mechanism of action**: 1. It inhibits the enzyme **Cyclooxygenase (COX)**, thereby reducing the synthesis of prostaglandins. 2. It acts as an **antagonist at prostaglandin receptors**, directly blocking the action of pre-formed prostaglandins on the myometrium. **Analysis of Incorrect Options:** * **A. Indomethacin:** While a potent COX inhibitor, it is associated with a high incidence of systemic side effects (GI distress, frontal headaches, and dizziness), making it a second-line choice for routine menstrual pain. * **B. Ketorolac:** This is an extremely potent analgesic primarily used for short-term management of severe acute pain (post-operative). It is not the standard of care for dysmenorrhea due to its high risk of nephrotoxicity and GI bleeding. * **D. Naproxen:** Although effective and frequently used for dysmenorrhea due to its long half-life, it lacks the specific receptor-blocking property of Mefenamic acid. **High-Yield Clinical Pearls for NEET-PG:** * **Mefenamic Acid (Fenamate):** Also used in Menorrhagia as it reduces blood loss by 20-30%. * **Side Effect:** A unique side effect of Mefenamic acid is **diarrhea** and occasionally hemolytic anemia. * **DOC for PDA:** Ibuprofen (or Indomethacin) is the drug of choice for the closure of Patent Ductus Arteriosus. * **DOC for Acute Gout:** NSAIDs (like Indomethacin or Naproxen) are first-line, but Mefenamic acid is not typically used.

Question 6: What is the recommended treatment for headache in a patient with peptic ulcer disease?

A. Microline aspirin
B. Propoxyphene (Correct Answer)
C. Paracetamol
D. Oxyphenbutazone

Explanation: ### Explanation The management of pain in patients with **Peptic Ulcer Disease (PUD)** requires avoiding drugs that inhibit prostaglandin synthesis in the gastric mucosa, as prostaglandins (PGE2 and PGI2) are essential for maintaining the gastric mucosal barrier. **Why Propoxyphene is Correct:** Propoxyphene is a mild **opioid analgesic**. Unlike Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), opioids do not inhibit the cyclooxygenase (COX) enzymes. Therefore, they do not interfere with gastric mucus production or increase acid secretion, making them safe for patients with active or history of peptic ulcers. While Paracetamol is often a first-line choice, in the context of this specific question and provided options, Propoxyphene is the designated correct answer as a non-ulcerogenic alternative. **Analysis of Incorrect Options:** * **A. Microline Aspirin:** Aspirin is a non-selective COX inhibitor. It causes direct mucosal irritation and systemic inhibition of protective prostaglandins, significantly increasing the risk of gastric bleeding and perforation. * **C. Paracetamol:** While Paracetamol (Acetaminophen) is generally safe for the stomach, it is primarily an antipyretic with weak peripheral anti-inflammatory action. In many standardized clinical scenarios, if a stronger analgesic is needed or if the question follows older pharmacological classifications, a mild opioid is highlighted. * **D. Oxyphenbutazone:** This is a potent NSAID (a metabolite of Phenylbutazone) with high gastric toxicity. It is notorious for causing peptic ulcers and bone marrow suppression. **NEET-PG High-Yield Pearls:** * **Drug of choice for pain in PUD:** Paracetamol (first-line) or Opioids (if stronger analgesia is needed). * **Safest NSAID for GI tract:** Selective COX-2 inhibitors (e.g., Celecoxib), though they carry cardiovascular risks. * **Prophylaxis:** If an NSAID must be used in a PUD patient, it should be co-administered with a **Proton Pump Inhibitor (PPI)** or **Misoprostol** (PGE1 analogue).

Question 7: Aseptic meningitis has been reported as an adverse effect of which of the following drugs?

A. Ibuprofen (Correct Answer)
B. Paracetamol
C. Ketorolac
D. Nimesulide

Explanation: ### Explanation **Correct Answer: A. Ibuprofen** **Mechanism and Concept:** Drug-Induced Aseptic Meningitis (DIAM) is a rare but well-documented hypersensitivity reaction (Type III or IV). **Ibuprofen** is the most common pharmacological trigger for this condition [2]. It typically presents with classic meningeal signs—fever, headache, neck stiffness, and altered mental status—but with "sterile" cerebrospinal fluid (negative cultures). While the exact pathogenesis is not fully understood, it is most frequently observed in patients with underlying autoimmune conditions, particularly **Systemic Lupus Erythematosus (SLE)** and Mixed Connective Tissue Disease (MCTD). **Analysis of Incorrect Options:** * **B. Paracetamol (Acetaminophen):** Primarily an antipyretic and analgesic with weak peripheral anti-inflammatory action [1]. Its main life-threatening adverse effect is dose-dependent **hepatotoxicity** (NAPQI accumulation), not aseptic meningitis. * **C. Ketorolac:** A potent NSAID used for short-term management of severe pain. While it shares the side-effect profile of other NSAIDs (gastric ulcers, renal impairment), it is not classically associated with aseptic meningitis. * **D. Nimesulide:** A selective COX-2 inhibitor. Its most significant "red flag" side effect is **fulminant hepatic failure**, which has led to its ban or restricted use in many countries. **High-Yield Clinical Pearls for NEET-PG:** * **DIAM Triggers:** Besides Ibuprofen, other drugs to remember include **IVIG (Intravenous Immunoglobulin)**, OKT3 monoclonal antibodies, and certain antibiotics like Trimethoprim-Sulfamethoxazole. * **CSF Findings in DIAM:** Pleocytosis (usually neutrophilic or lymphocytic), elevated protein, and **normal glucose levels** (unlike bacterial meningitis). * **Management:** Symptoms typically resolve within 24–48 hours upon discontinuation of the offending drug. * **NSAID of choice for Patent Ductus Arteriosus (PDA):** Indomethacin or Ibuprofen. * **NSAID with least GI toxicity:** Celecoxib (COX-2 selective) [3].

Question 8: Which of the following is a spasmolytic analgesic?

A. Dicyclomine (Correct Answer)
B. Physostigmine
C. Tropicamide
D. None of the above

Explanation: **Explanation:** **Dicyclomine** is the correct answer because it is a tertiary amine antimuscarinic agent that functions as a **spasmolytic (antispasmodic)**. It works by antagonizing muscarinic (M3) receptors on smooth muscles and exerts a direct relaxant effect on the gastrointestinal tract. In clinical practice, it is frequently used to relieve smooth muscle spasms and associated pain in conditions like irritable bowel syndrome (IBS) and GI colic, earning it the classification of a "spasmolytic analgesic." **Analysis of Incorrect Options:** * **Physostigmine:** This is a reversible anticholinesterase (parasympathomimetic). Instead of relieving spasms, it increases acetylcholine levels, which would actually increase GI motility and potentially worsen cramping. It is primarily used as an antidote for atropine poisoning. * **Tropicamide:** This is a short-acting antimuscarinic used exclusively in ophthalmology as a mydriatic (to dilate the pupil) and cycloplegic. It has no systemic role as a spasmolytic analgesic. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Dicyclomine reduces GI tone and amplitude of contractions without significantly affecting gastric acid secretion. * **Contraindications:** Like all anticholinergics, it should be avoided in patients with **Glaucoma** (can increase intraocular pressure), **Prostatic Hyperplasia** (can cause urinary retention), and **Myasthenia Gravis**. * **Other Spasmolytics:** Other drugs in this category frequently tested include **Hyoscine (Scopolamine)** and **Drotaverine** (a PDE-4 inhibitor).

Question 9: Gold compounds are used in the management of which condition?

A. Ankylosing Spondylitis
B. Rheumatoid Arthritis (Correct Answer)
C. Psoriatic arthritis
D. Rheumatic arthritis

Explanation: **Explanation:** **Gold compounds** (Chrysotherapy), such as **Auranofin** (oral) and **Sodium aurothiomalate** (injectable), are classified as older Disease-Modifying Anti-Rheumatic Drugs (DMARDs). **Why Rheumatoid Arthritis (RA) is correct:** Gold compounds work by inhibiting macrophage phagocytosis and lysosomal enzyme release, which slows the progression of bone and cartilage destruction in RA. While they were once a mainstay for inducing remission in active RA, they have largely been replaced by more effective and less toxic agents like Methotrexate. **Analysis of Incorrect Options:** * **Ankylosing Spondylitis:** This is a seronegative spondyloarthropathy. The primary treatments are NSAIDs and TNF-alpha inhibitors (e.g., Etanercept). Gold salts have no proven efficacy in axial skeletal involvement. * **Psoriatic Arthritis:** While some DMARDs are used here, Gold is not a standard or effective treatment for the cutaneous or articular manifestations of psoriasis. * **Rheumatic Arthritis (Rheumatic Fever):** This is an inflammatory response to a Group A Streptococcal infection. The management focuses on antibiotics (Penicillin) and salicylates (Aspirin) for joint pain, not DMARDs. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Gold salts are taken up by macrophages (forming "Aurosomes") and inhibit NF-kB signaling. * **Toxicity (High Yield):** The most common side effects are **dermatitis** (pruritic rash), **nephrotoxicity** (membranous glomerulonephritis leading to proteinuria), and **hematological disorders** (aplastic anemia). * **Current Status:** Gold is now considered a "reserve drug" due to its slow onset of action (3–6 months) and significant side-effect profile.

Question 10: Which of the following is an analgesic that does not inhibit prostaglandin synthesis?

A. Nefopam (Correct Answer)
B. Tenoxicam
C. Ketorolac
D. Piroxicam

Explanation: ### Explanation **1. Why Nefopam is Correct:** Nefopam is a **non-opioid, non-NSAID** centrally acting analgesic. Unlike NSAIDs, its mechanism of action does not involve the inhibition of cyclooxygenase (COX) enzymes or prostaglandin synthesis. Instead, it acts primarily by inhibiting the reuptake of **serotonin, norepinephrine, and dopamine** (triple monoamine reuptake inhibitor). It also modulates NMDA receptors and sodium/calcium channels. This unique profile makes it useful for acute pain management without the gastrointestinal or anti-platelet side effects associated with prostaglandin inhibition. **2. Why the Other Options are Incorrect:** * **Tenoxicam & Piroxicam (Options B & D):** These are long-acting NSAIDs belonging to the **Oxicam** class. They are potent inhibitors of both COX-1 and COX-2 enzymes, thereby reducing prostaglandin synthesis. * **Ketorolac (Option C):** This is a **Pyrrolo-pyrrole** derivative NSAID known for its powerful analgesic efficacy (comparable to low-dose morphine). It is a non-selective COX inhibitor that significantly blocks prostaglandin production. **3. High-Yield Clinical Pearls for NEET-PG:** * **Nefopam & Shivering:** A high-yield clinical use of Nefopam is its effectiveness in treating **post-operative shivering**, as it resets the shivering threshold in the hypothalamus. * **Contraindications:** Due to its sympathomimetic effects (norepinephrine reuptake inhibition), it should be avoided in patients with **convulsions, glaucoma, or those taking MAO inhibitors.** * **Side Effects:** Common side effects include tachycardia, dry mouth, and urinary retention (anticholinergic-like effects). * **Analgesic Ladder:** Nefopam is often used as an "adjunct" in multimodal analgesia to reduce opioid requirements (opioid-sparing effect).

Practice by Chapter

NSAIDs: Classification and Mechanism

Practice Questions

COX-2 Selective Inhibitors

Practice Questions

Acetaminophen (Paracetamol)

Practice Questions

Opioid Analgesics and Antagonists

Practice Questions

Drugs Used in Gout and Hyperuricemia

Practice Questions

Drugs Used in Rheumatoid Arthritis

Practice Questions

Disease-Modifying Antirheumatic Drugs

Practice Questions

Glucocorticoids as Anti-inflammatory Agents

Practice Questions

Migraine Therapeutics

Practice Questions

Neuropathic Pain Management

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free